Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring
2 findings from 1 review
Pain · people with burn wounds likely to develop hypertrophic scarring
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pruritus · people with burn wounds likely to develop hypertrophic scarring
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with burn wounds likely to develop hypertrophic scarring
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Adherence · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy may leads to lower overall survival compared with chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specificadverse events: gastrointestinal perforations or fistulae compared with chemotherapy (moderate certainty).
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: serious thromboembolic events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: hypertension compared with chemotherapy (moderate certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher serious adverse events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Economic evaluation · women with persistent, recurrent, or metastatic cervical cancer
1 finding from 1 review
All‐cause mortality · people with cancer who have febrile neutropenia
Pre‐emptive antifungal therapy showed no clear difference in all‐cause mortality compared with empirical antifungal therapy (low certainty).
1 finding from 1 review
Mortality ascribed to fungal infection · people with cancer who have febrile neutropenia
Pre‐emptive antifungal therapy showed no clear difference in mortality ascribed to fungal infection compared with empirical antifungal therapy (low certainty).
1 finding from 1 review
Proportion of antifungal agent use (other than prophylactic use) · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes proportion of antifungal agent use (other than prophylactic use) compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Duration of antifungal use (days) · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes duration of antifungal use (days) compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Invasive fungal infection detection · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes invasive fungal infection detection compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Adverse effects · people with cancer who have febrile neutropenia
1 finding from 1 review
Live birth rate · patients with endometriosis prior to standard IVF/ICSI
It is very uncertain whether long‐term GnRH agonist therapy changes live birth rate compared with no additional therapy (very low certainty).
1 finding from 1 review